The importance of androgen receptor (AR) signaling in regulating the growth and survival of prostate cancer cells cannot be overstated [2], making androgen deprivation therapy (ADT), which targets this pathway, a cornerstone in the management of both early-stage and metastatic PCa [3]. Here, AR is linked to prostate carcinoma.